PT Kalbe Farma Tbk Overview
Valuation check: PTKFF's ROE is 12.09%, below the Healthcare sector average of 20.86%.
Get informed when a big investor buys or sells
+ Follow12.09%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
PT Kalbe Farma Tbk (PTKFF) currently reports a ROE of 12.09%. That is below the Healthcare sector average of 20.86%. Use the charts on this page to explore PT Kalbe Farma Tbk's ROE history and peer comparisons.
PT Kalbe Farma Tbk's ROE of 12.09% is lower than the Healthcare sector average of 20.86%. That is roughly 42.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but PT Kalbe Farma Tbk's current 12.09% should be judged against Healthcare norms (sector average: 20.86%) and against PTKFF's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of 12.09%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 20.86%. From there, open related valuation or income-statement pages for PT Kalbe Farma Tbk, and consider following PTKFF for alerts when major investors trade the stock.
PT Kalbe Farma Tbk is classified in the Healthcare sector. On ROE, it currently shows 12.09% versus a sector average near 20.86%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PTKFF with unrelated industries.
